Over $1.6 million has been received from the NIH’s National Heart, Lung, and Blood Institute (NHLBI) for the 5-year Cardiothoracic Surgery Research Training Program. This research training grant is focused on the next generation of academic cardiac and thoracic surgeons and will be led by the following team which includes four McGowan Institute for Regenerative Medicine affiliated faculty members:
LyGenesis is a clinical-stage biotechnology company whose cell therapies use patients’ lymph nodes as bioreactors to regrow functioning ectopic organs. LyGenesis’s lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end stage liver disease. LyGenesis was built on nearly a decade of groundbreaking academic research by McGowan Institute for Regenerative Medicine faculty member Eric Lagasse, PharmD, PhD, Associate Professor in the Department of Pathology at the University of Pittsburgh and LyGenesis Founder and Chief Scientific Officer.
Maddie Cramer, a doctoral student in the Bioengineering Department at the University of Pittsburgh and a team member in the laboratory of Stephen Badylak, DVM, PhD, MD, will receive the Outstanding Student Award from TERMIS-AA. Dr. Badylak is a deputy director of the McGowan Institute for Regenerative Medicine, professor in the Department of Surgery, and director of the Center for Pre-Clinical Tissue Engineering within the Institute.
During the Magee-Womens Summit, the Magee-Womens Research Institute (MWRI) awarded the $1 million Magee Prize to an international team led by McGowan Institute for Regenerative Medicine affiliated faculty member Pamela Moalli, MD, PhD, director of urogynecology and pelvic reconstruction surgery at UPMC Magee-Womens Hospital and MWRI. The team is working to develop new biomaterials to repair tissue loss in women with compromised vaginal structure and function.
Pediatric Device Innovators Forum (PDIF) is a recurring collaborative educational experience designed to connect and foster synergy among innovators across the technology development ecosystem who are interested in pediatric medical device development.
ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced that the Food and Drug Administration (FDA) has granted the company De Novo clearance for the Hemolung Respiratory Assist System. This system was developed at the McGowan Institute for Regenerative Medicine by a team of researchers led by faculty member William Federspiel, PhD, the company’s cofounder and professor of bioengineering, chemical engineering, critical care medicine, and the Clinical Translation Institute at the University of Pittsburgh. Dr. Federspiel is also the director of the Medical Devices Laboratory at the McGowan Institute.
From the author of the GI Bill of Rights to a former Army Surgeon General, veterans have shaped the trajectory of the University of Pittsburgh — and the world. As Pitt honored those who have served this Veterans Day, the Office of Veterans Services and Archives and Special Collections highlighted veterans from the 20th and 21st centuries who have made a major difference in Pitt’s history. Three of those veterans are McGowan Institute for Regenerative Medicine affiliated faculty members.
Eighteen faculty members in the natural sciences departments in the University of Pittsburgh’s Dietrich School of Arts & Sciences were recently awarded the Discipline-based Science Education Research (dB-SERC) Leader Award. McGowan Institute for Regenerative Medicine affiliated faculty member Burhan Gharaibeh, PhD, faculty member in the Department of Biological Sciences and an adjunct faculty member in the Department of Bioengineering at the University of Pittsburgh, is one of the awardees.
By combining computational and experimental approaches, University of Pittsburgh School of Medicine and Prairie View A&M University researchers identified cancer drugs that show promise for treating pulmonary hypertension, or PH, a rare and incurable lung disease.
CATER Trainee Michael Behrens defended his dissertation on Tuesday, November 9, 2021. The presentation was titled, “Engineering Automated Microrobotic Systems with Machine Learning-Based Control for Biomedical Applications.” The CATER Program would like congratulate Michael, and we wish him much success for his future!
